Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
78.21
+1.06 (1.37%)
Jun 27, 2025, 4:00 PM - Market closed
Edwards Lifesciences Employees
Edwards Lifesciences had 15,800 employees as of December 31, 2024. The number of employees decreased by 4,000 or -20.20% compared to the previous year.
Employees
15,800
Change (1Y)
-4,000
Growth (1Y)
-20.20%
Revenue / Employee
$349,513
Profits / Employee
$264,601
Market Cap
45.88B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 15,800 | -4,000 | -20.20% |
Dec 31, 2023 | 19,800 | 2,500 | 14.45% |
Dec 31, 2022 | 17,300 | 1,600 | 10.19% |
Dec 31, 2021 | 15,700 | 800 | 5.37% |
Dec 31, 2020 | 14,900 | 1,000 | 7.19% |
Dec 31, 2019 | 13,900 | 1,100 | 8.59% |
Dec 31, 2018 | 12,800 | 600 | 4.92% |
Dec 31, 2017 | 12,200 | 1,100 | 9.91% |
Dec 31, 2016 | 11,100 | 1,300 | 13.27% |
Dec 31, 2015 | 9,800 | 700 | 7.69% |
Dec 31, 2014 | 9,100 | 500 | 5.81% |
Dec 31, 2013 | 8,600 | 400 | 4.88% |
Dec 31, 2012 | 8,200 | 400 | 5.13% |
Dec 31, 2011 | 7,800 | 800 | 11.43% |
Dec 31, 2010 | 7,000 | 600 | 9.38% |
Dec 31, 2009 | 6,400 | 200 | 3.23% |
Dec 31, 2008 | 6,200 | 600 | 10.71% |
Dec 31, 2007 | 5,600 | 50 | 0.90% |
Dec 31, 2006 | 5,550 | 150 | 2.78% |
Dec 31, 2005 | 5,400 | 200 | 3.85% |
Dec 31, 2004 | 5,200 | 200 | 4.00% |
Dec 31, 2003 | 5,000 | 0 | - |
Dec 31, 2002 | 5,000 | 189 | 3.93% |
Dec 31, 2001 | 4,811 | -289 | -5.67% |
Dec 31, 2000 | 5,100 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
EW News
- 23 days ago - Edwards Lifesciences: With A Heart Beating Strong And Steady - Seeking Alpha
- 5 weeks ago - Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes - Business Wire
- 7 weeks ago - Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference - Business Wire
- 2 months ago - Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis - Business Wire
- 2 months ago - Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens - Benzinga
- 2 months ago - Edwards Lifesciences Corporation (EW) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Edwards Lifesciences raises 2025 sales forecast after robust quarter - Reuters
- 2 months ago - Edwards Lifesciences Reports First Quarter Results - Business Wire